Notable Reporting: ST Jude Medical Inc (NYSE:STJ) Q2 2016 Sentiment Report

November 25, 2016 - By kentuckypostne   ·   0 Comments

Notable Reporting: ST Jude Medical Inc (NYSE:STJ)  Q2 2016 Sentiment Report

Sentiment for ST Jude Medical Inc (NYSE:STJ)

ST Jude Medical Inc (NYSE:STJ) institutional sentiment decreased to 0.69 in 2016 Q2. Its down -0.17, from 0.86 in 2016Q1. The ratio is negative, as 251 hedge funds opened new and increased positions, while 291 sold and reduced their positions in ST Jude Medical Inc. The hedge funds in our partner’s database now hold: 256.31 million shares, up from 238.60 million shares in 2016Q1. Also, the number of hedge funds holding ST Jude Medical Inc in their top 10 positions increased from 9 to 31 for an increase of 22. Sold All: 73 Reduced: 218 Increased: 143 New Position: 108.

St. Jude Medical, Inc. is focused on the development, manufacture and distribution of cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. The company has a market cap of $23.23 billion.

About 373,846 shares traded hands. St. Jude Medical, Inc. (NYSE:STJ) has risen 31.89% since April 22, 2016 and is uptrending. It has outperformed by 26.48% the S&P500.

Analysts await St. Jude Medical, Inc. (NYSE:STJ) to report earnings on January, 25. They expect $1.07 EPS, up 4.90% or $0.05 from last year’s $1.02 per share. STJ’s profit will be $310.08 million for 18.73 P/E if the $1.07 EPS becomes a reality. After $0.99 actual EPS reported by St. Jude Medical, Inc. for the previous quarter, Wall Street now forecasts 8.08% EPS growth.

According to Zacks Investment Research, “St. Jude Medical, Inc. is dedicated to making life better for cardiac, neurological and chronic pain patients worldwide through excellence in medical device technology and services. The Company has five major focus areas that include cardiac rhythm management, atrial fibrillation, cardiac surgery, cardiology and neuromodulation.”

Manikay Partners Llc holds 8.37% of its portfolio in St. Jude Medical, Inc. for 1.41 million shares. Omni Partners Llp owns 31.22 million shares or 8.04% of their US portfolio. Moreover, Cowen Group Inc. has 7.89% invested in the company for 1.50 million shares. The Minnesota-based Perkins Capital Management Inc has invested 5.96% in the stock. Havens Advisors Llc, a New York-based fund reported 96,200 shares.#img1#

St. Jude Medical, Inc. (NYSE:STJ) Ratings Coverage

Ratings analysis reveals 20% of St. Jude Medical Inc.’s analysts are positive. Out of 20 Wall Street analysts rating St. Jude Medical Inc., 4 give it “Buy”, 0 “Sell” rating, while 16 recommend “Hold”. The lowest target is $57 while the high is $92. The stock’s average target of $75.56 is -5.75% below today’s ($80.17) share price. STJ was included in 45 notes of analysts from July 21, 2015. Deutsche Bank maintained the stock with “Hold” rating in Saturday, August 29 report. Oppenheimer maintained the shares of STJ in a report on Thursday, January 28 with “Perform” rating. RBC Capital Markets maintained the stock with “Sector Perform” rating in Monday, January 25 report. The firm earned “Neutral” rating on Friday, July 15 by Wedbush. BTIG Research maintained St. Jude Medical, Inc. (NYSE:STJ) on Sunday, August 9 with “Buy” rating. The firm earned “Hold” rating on Monday, August 24 by Zacks. The rating was maintained by Barclays Capital with “Overweight” on Thursday, October 22. The company was downgraded on Tuesday, January 19 by Wells Fargo. The firm has “Buy” rating given on Friday, August 28 by S&P Research. The rating was downgraded by Stifel Nicolaus to “Hold” on Thursday, October 22.

STJ Company Profile

St. Jude Medical, Inc., incorporated on May 12, 1976, is focused on the development, manufacture and distribution of cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. The Company’s product categories include tachycardia implantable cardioverter defibrillator (ICD) systems; atrial fibrillation (AF) products (electrophysiology (EP) introducers and catheters, advanced cardiac mapping, navigation and recording systems and ablation systems); bradycardia pacemaker (pacemaker) systems; vascular products (vascular closure products, pressure measurement guidewires, optical coherence tomography (OCT) imaging products, vascular plugs, heart failure monitoring devices and other vascular accessories); structural heart products (heart valve replacement and repair products and structural heart defect devices); neuromodulation products (spinal cord stimulation and radiofrequency ablation to treat chronic pain and deep brain stimulation to treat movement disorders), and Thoratec products (ventricular assist devices and percutaneous heart pumps).

Another recent and important St. Jude Medical, Inc. (NYSE:STJ) news was published by Reuters.com which published an article titled: “EU regulator conditionally approves Abbott’s purchase of St Jude” on November 23, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By kentuckypostne


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>